Lifecore Biomedical, Inc. LFCR
NASDAQ
| 06/30/2026 | 03/31/2026 | 09/30/2025 | 09/30/2025 | 05/25/2025 | |
|---|---|---|---|---|---|
| Net Income | -- | -- | -32.48M | -32.48M | -38.72M |
| Total Depreciation and Amortization | -- | -- | 8.02M | 8.02M | 8.03M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -- | 38.19M | 38.19M | 35.18M |
| Change in Net Operating Assets | -- | -- | -11.52M | -11.52M | -4.70M |
| Cash from Operations | -- | -- | 2.20M | 2.20M | -206.00K |
| Capital Expenditure | -- | -- | -11.76M | -11.76M | -13.42M |
| Sale of Property, Plant, and Equipment | -- | -- | 7.00M | 7.00M | 7.00M |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -4.76M | -4.76M | -6.42M |
| Total Debt Issued | -- | -- | 138.75M | 138.75M | 128.57M |
| Total Debt Repaid | -- | -- | -157.86M | -157.86M | -145.76M |
| Issuance of Common Stock | -- | -- | 23.86M | 23.86M | 23.86M |
| Repurchase of Common Stock | -- | -- | -1.85M | -1.85M | -1.28M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 1.04M | 1.04M | 1.04M |
| Cash from Financing | -- | -- | 3.94M | 3.94M | 6.42M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -- | 1.38M | 1.38M | -197.00K |